Email This Article

Headlines & Perspectives
Biotech Mailbag: Study Boosts ImmunoGen
By Adam Feuerstein
10/17/08 - 11:37 AM EDT
Genentech is advancing T-DM1, which uses ImmunoGen technology, into a phase III study as a second-line treatment for Her-2 positive metastatic breast cancer.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,464.40 1,110.63 2,176.05 32.25
Oil *
75.11
UP
30.69
UP
4.98
UP
6.87
DOWN
0.54
10 Yr
3.22%
SPDR Gold
116.62
+0.29%
+0.45%
+0.32%
-1.65%
Data delayed 20 minutes

Brokerage Partners